ReviewJournal of diabetes2025
Potential Significance of Targeting Ferroptosis for Intervention of Diabetic Cardiomyopathy.
Review in Journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Baicalein Attenuates High Glucose and Sodium Palmitate-Induced Ferroptosis in Cardiomyocytes via the Nrf2/SLC7A11/GPX4 Signaling Pathway.International journal of molecular sciences · 2026Article
- METTL14 Hinders DCM Progression via Mediating the m6A Methylation of NRG4 in HG-Induced H9C2 Cells.Molecular biotechnology · 2026Article
- Ferroptosis in Diabetic Cardiomyopathy and Atherosclerosis: Mechanisms and Clinical Prospects.International journal of molecular sciences · 2025Review
- Potential Significance of Targeting Ferroptosis for Intervention of Diabetic Cardiomyopathy.Journal of diabetes · 2025Review
- Mechanisms of circular RNAs in diabetic cardiomyopathy: biological characteristics and clinical prospects.Frontiers in genetics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundDiabetes represents a significant global health concern, with diabetic cardiomyopathy (DCM) emerging as a primary cause of mortality among individuals with diabetes. Despite the prevalence of DCM, advancements in therapeutic and preventative strategies remain constrained.
methodsRecent studies were reviewed to provide a comprehensive summary of pathogenesis and clinical treatment of DCM, effect of ferroptosis, and potential value of ferroptosis inhibitors in DCM intervention.
resultsA growing body of research indicates that oxidative stress, inflammatory reactions, and other factors play a role in the onset and progression of DCM. Oxidative stress within cardiomyocytes is a primary mechanism implicated in the development of DCM, whereby heightened intracellular reactive oxygen species (ROS) facilitate cell death via ferroptosis. Ferroptosis inhibitors hold great promise as therapeutic agents.
conclusionsThis review provides an overview of the involvement of iron homeostasis regulation, oxidative stress, and ferroptosis in DCM, and the significance of ferroptosis in the prevention and treatment of DCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.